20 December 2024 | By Catherine Eckford (European Pharmaceutical Review)
The new agreement between Bristol Myers Squibb and BioArctic is set to advance development of anti-amyloid-beta antibody treatments, which have shown symptomatic benefit in Alzheimer's.